Interest in HIV vaccines among injection drug users in Baltimore, Maryland

D. Vlahov, J. Astemborski, L. Solomon, Noya Galai, L. Basarab, Kenrad Edwin Nelson

Research output: Contribution to journalArticle

Abstract

To gauge interest about participation in human immunodeficiency virus type 1 (HIV vaccines, we interviewed 375 HIV-seronegative injecting drug users who are participants in an ongoing longitudinal study of HIV infection. Nearly all (93%) responded that they thought it likely that an HIV vaccine would become available, and 85% expressed interest in participating in a study of vaccine effectiveness. However, levels of interest decreased to 47% when respondents were informed that the vaccine might result in a positive HIV test and to 27% when offered to be in a study where the vaccine might contain a piece of the virus. Factors that increased interest in trial participation included assurances of confidentiality, being fully informed about the protocol and remuneration. Most respondents (78%) felt that injecting drug users would maintain other risk reduction activities (e.g., condom use) if they participated in a vaccine study. These data suggest a high level of interest for participation in HIV vaccine trials, but that more education about vaccines and the risks involved is needed. Ongoing communication with the community and responsiveness to community concerns is crucial to achieve a successful vaccine study.

Original languageEnglish (US)
JournalAIDS Research and Human Retroviruses
Volume10
Issue numberSUPPL. 2
StatePublished - 1994
Externally publishedYes

Fingerprint

AIDS Vaccines
Baltimore
Drug Users
Vaccines
Injections
HIV
Remuneration
Confidentiality
Condoms
Risk Reduction Behavior
HIV Infections
Longitudinal Studies
HIV-1
Communication
Viruses
Education

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Interest in HIV vaccines among injection drug users in Baltimore, Maryland. / Vlahov, D.; Astemborski, J.; Solomon, L.; Galai, Noya; Basarab, L.; Nelson, Kenrad Edwin.

In: AIDS Research and Human Retroviruses, Vol. 10, No. SUPPL. 2, 1994.

Research output: Contribution to journalArticle

@article{43ba4fbe0cc247c28152a3bb25ddaca0,
title = "Interest in HIV vaccines among injection drug users in Baltimore, Maryland",
abstract = "To gauge interest about participation in human immunodeficiency virus type 1 (HIV vaccines, we interviewed 375 HIV-seronegative injecting drug users who are participants in an ongoing longitudinal study of HIV infection. Nearly all (93{\%}) responded that they thought it likely that an HIV vaccine would become available, and 85{\%} expressed interest in participating in a study of vaccine effectiveness. However, levels of interest decreased to 47{\%} when respondents were informed that the vaccine might result in a positive HIV test and to 27{\%} when offered to be in a study where the vaccine might contain a piece of the virus. Factors that increased interest in trial participation included assurances of confidentiality, being fully informed about the protocol and remuneration. Most respondents (78{\%}) felt that injecting drug users would maintain other risk reduction activities (e.g., condom use) if they participated in a vaccine study. These data suggest a high level of interest for participation in HIV vaccine trials, but that more education about vaccines and the risks involved is needed. Ongoing communication with the community and responsiveness to community concerns is crucial to achieve a successful vaccine study.",
author = "D. Vlahov and J. Astemborski and L. Solomon and Noya Galai and L. Basarab and Nelson, {Kenrad Edwin}",
year = "1994",
language = "English (US)",
volume = "10",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Interest in HIV vaccines among injection drug users in Baltimore, Maryland

AU - Vlahov, D.

AU - Astemborski, J.

AU - Solomon, L.

AU - Galai, Noya

AU - Basarab, L.

AU - Nelson, Kenrad Edwin

PY - 1994

Y1 - 1994

N2 - To gauge interest about participation in human immunodeficiency virus type 1 (HIV vaccines, we interviewed 375 HIV-seronegative injecting drug users who are participants in an ongoing longitudinal study of HIV infection. Nearly all (93%) responded that they thought it likely that an HIV vaccine would become available, and 85% expressed interest in participating in a study of vaccine effectiveness. However, levels of interest decreased to 47% when respondents were informed that the vaccine might result in a positive HIV test and to 27% when offered to be in a study where the vaccine might contain a piece of the virus. Factors that increased interest in trial participation included assurances of confidentiality, being fully informed about the protocol and remuneration. Most respondents (78%) felt that injecting drug users would maintain other risk reduction activities (e.g., condom use) if they participated in a vaccine study. These data suggest a high level of interest for participation in HIV vaccine trials, but that more education about vaccines and the risks involved is needed. Ongoing communication with the community and responsiveness to community concerns is crucial to achieve a successful vaccine study.

AB - To gauge interest about participation in human immunodeficiency virus type 1 (HIV vaccines, we interviewed 375 HIV-seronegative injecting drug users who are participants in an ongoing longitudinal study of HIV infection. Nearly all (93%) responded that they thought it likely that an HIV vaccine would become available, and 85% expressed interest in participating in a study of vaccine effectiveness. However, levels of interest decreased to 47% when respondents were informed that the vaccine might result in a positive HIV test and to 27% when offered to be in a study where the vaccine might contain a piece of the virus. Factors that increased interest in trial participation included assurances of confidentiality, being fully informed about the protocol and remuneration. Most respondents (78%) felt that injecting drug users would maintain other risk reduction activities (e.g., condom use) if they participated in a vaccine study. These data suggest a high level of interest for participation in HIV vaccine trials, but that more education about vaccines and the risks involved is needed. Ongoing communication with the community and responsiveness to community concerns is crucial to achieve a successful vaccine study.

UR - http://www.scopus.com/inward/record.url?scp=0028028083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028028083&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - SUPPL. 2

ER -